MedTrace Logo

GLPG0259 Solid Formulation Bioavailability and Food Effect

NCT01024517 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2010-04-27

No results posted yet for this study

Summary

The purpose of the study is to compare the pharmacokinetics of GLPG0259 as a solid dosage formulation (with and without food)and an oral solution, and to assess its safety and tolerability.

Conditions

  • Healthy

Interventions

DRUG

GLPG0259 solution

single oral dose, GLPG0259, 50 mg oral solution

DRUG

GLPG0259

single oral dose, GLPG0259, 50 mg solid formulation

Sponsors & Collaborators

  • Galapagos NV

    lead INDUSTRY

Principal Investigators

  • Johan Beetens, PharmD, PhD · Galapagos NV

  • Wouter Haazen, MD · SGS Stuivenberg

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2009-12-31
Completion
2010-02-28

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01024517 on ClinicalTrials.gov